https://pharminent.com/81130-2/ 2026-05-27T21:43:03Z Pharminent en 2026-05-27T21:42:57Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-27-2026/ 2026-05-27T17:31:58Z Pharminent en Strategic News Watch • May 27, 2026 2026-05-27T17:31:53Z Blog https://pharminent.com/apogee-investors-riled-by-1-3b-royalty-deal-as-eczema-drug-matches-lillys-ebglyss/ 2026-05-27T16:09:42Z Pharminent en Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly's Ebglyss 2026-05-27T15:15:18Z Blog https://pharminent.com/kardigan-targets-ipo-to-support-cardiology-pipeline-progression/ 2026-05-27T16:09:48Z Pharminent en Kardigan targets IPO to support cardiology pipeline progression 2026-05-27T14:06:51Z Blog https://pharminent.com/fda-delays-verdict-on-az-breast-cancer-drug/ 2026-05-27T16:09:52Z Pharminent en FDA delays verdict on AZ breast cancer drug 2026-05-27T12:47:03Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-26-2026/ 2026-05-27T01:14:59Z Pharminent en Oncology Intelligence Digest • May 26, 2026 2026-05-27T01:14:56Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-26-2026/ 2026-05-26T18:53:51Z Pharminent en Strategic News Watch • May 26, 2026 2026-05-26T18:53:47Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-may-25-2026/ 2026-05-26T16:19:08Z Pharminent en Rare Disease & Gene Therapy Digest • May 25, 2026 2026-05-26T16:19:04Z Blog https://pharminent.com/early-data-for-heart-drug-affirm-lillys-billion-dollar-bet-on-verve/ 2026-05-27T16:12:19Z Pharminent en Early data for heart drug affirm Lilly's billion-dollar bet on Verve 2026-05-26T15:56:30Z Blog https://pharminent.com/eli-lilly-to-buy-trio-of-vaccine-developers-in-3-8bn-outlay/ 2026-05-26T14:48:59Z Pharminent en Eli Lilly to buy trio of vaccine developers in $3.8bn outlay 2026-05-26T12:28:39Z Blog https://pharminent.com/arthrosi-drug-trial-in-gout-delivers-for-new-owner-sobi/ 2026-05-27T01:55:38Z Pharminent en Arthrosi drug trial in gout delivers for new owner Sobi 2026-05-26T11:27:14Z Blog https://pharminent.com/lillys-verve-gambit-pays-off-as-base-editor-cuts-cholesterol-in-early-study/ 2026-05-26T14:49:04Z Pharminent en Lilly's Verve gambit pays off as base editor cuts cholesterol in early study 2026-05-26T11:00:42Z Blog https://pharminent.com/pierre-fabres-braftovi-gains-chmp-positive-opinion-for-mcrc-2/ 2026-05-27T01:55:10Z Pharminent en Pierre Fabre's Braftovi gains CHMP positive opinion for mCRC 2026-05-26T08:16:22Z Blog https://pharminent.com/all-eyes-on-revolution-bispecific-antibodies-and-more-at-asco26/ 2026-05-26T14:49:09Z Pharminent en All eyes on Revolution, bispecific antibodies and more at ASCO26 2026-05-26T04:32:00Z Blog https://pharminent.com/81075-2/ 2026-05-27T01:22:52Z Pharminent en 2026-05-26T01:19:14Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-25-2026/ 2026-05-25T19:35:14Z Pharminent en Strategic News Watch • May 25, 2026 2026-05-25T19:35:10Z Blog